The Company

About Oecona

Our services include health economic modelling, model adaptations and analyses, market access strategies, development of reimbursement applications and Health Technology Assessment (HTA) dossiers as well as health policy-oriented analyses. Oecona’s clients are companies in the life science industries both with and without representation in the Nordics. In the light of the steadily changing market access environment, Oecona provides guidance on how to effectively interact with the various governmental decision makers when a new product or indication shall be launched. Oecona is currently involved in several Nordic projects, developing HTA dossiers for submission to medicinal authorities in all Nordic markets.

Oecona also provides tender support services to pharmaceutical companies that want to take part in public tenders for hospital drugs in Norway.

Our team

Eivind Jørgensen

Managing Director

Eivind Jørgensen is trained as an economist (MPhil, University of Oslo) and has additional training in Health Economics (Diploma of HE, University of Tromsø) and Project Management (Norwegian Business School). He started working with health economic evaluation in AstraZeneca in 2000 and since then, he has been developing health economic models within disease areas such as, but not restricted to, lung cancer, breast cancer, asthma, COPD, Bipolar disease, depression, hypertension, hypercholesterolemia, hepatitis C and migraine. Eivind has an extensive experience with development of reimbursement applications and has submitted between 15 and 20 reimbursement applications to Norwegian authorities. Additionally, he served as the Head of the Health Economics Department in a consulting company and supervised a large number of reimbursement applications. Eivind has held both national and Nordic positions within health economics and market access.

TBC

Health Economist

(Sweden)

This position is to be confirmed.

Kari
Kollstad

Health Economist

Kari holds a Master in Health Economics, Policy and Management (University of Oslo), specialized in Economic Evaluation in Healthcare. She also has a degree in Pharmacy, and has 10 years of experience from the pharmaceutical industry.

She has knowledge within the pharmacy and wholesaler marked, regulatory affairs, economics, health economic modelling and health technology assessment.

Charlotte Indre Lund

Health Economist

Charlotte Indre Lund is a qualified Health Economist with specialisation in economic evaluation and holds MPhil degree in Health Economics from University of Oslo. Charlotte has experience with health economic modelling including expected value of perfect information analyses (EVPI &EVPPI) and budget impact analysis. She has developed expertise in data processing, management, and analysis of complex datasets through her scientific work as a Ph.D. fellow in Pain Epidemiology at Oslo University Hospital. Charlotte has been investigating the associations between sex hormones and chronic pain outcomes in adult women using data from The Tromsø Study (2007-2016), a large population-based questionnaire (Real World Evidence). Her first article has been featured as an Editor´s choice in the high impact journal PAIN.